Noxopharm Limited (ASX:NOX), an Australian clinical-stage biotechnology company, has issued 1,240,351 new fully paid ordinary shares in lieu of Directors' Fees, following shareholder approval granted at the company's 2026 Annual General Meeting held on 17 November 2026, the company disclosed on 20 November 2026.
Key Points
- Noxopharm issued 1,240,351 new fully paid shares in lieu of Directors' Fees on 20 November 2026.
- Shareholders approved the share issuance at the 2026 Annual General Meeting held on 17 November 2026.
- The shares were issued without disclosure under Part 6D.2 of the Corporations Act 2001 (Cth).
- The company confirmed compliance with Chapter 2M, section 674, and section 674A of the Corporations Act as at the date of the notice.
Share Issuance in Lieu of Directors' Fees
Noxopharm disclosed that it issued 1,240,351 new fully paid ordinary shares on 20 November 2026 in lieu of Directors' Fees. The issuance followed approval by shareholders at the company's 2026 Annual General Meeting, which was held on 17 November 2026. The shares were issued without disclosure under Part 6D.2 of the Corporations Act 2001 (Cth). The notice was filed by Company Secretary Shawn van Boheemen and was authorised for release by the Board of Noxopharm Limited.
Cleansing Notice Under Section 708A of the Corporations Act
Noxopharm provided a cleansing notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) in connection with the share issuance. According to the filing, the company confirmed that as at the date of the notice, there is no information constituting "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed under section 708A(6)(e). The company also confirmed compliance with the provisions of Chapter 2M of the Corporations Act as they apply to the company, as well as sections 674 and 674A of the Corporations Act.
Company Overview and Clinical Programs
Noxopharm is described in the filing as a clinical-stage Australian biotechnology company developing therapies for chronic inflammation, autoimmune diseases and cancer. The company's proprietary Sofra™ platform is designed to regulate innate immune signalling. Its lead clinical asset, SOF-SKN™, is a topical therapy being developed for cutaneous lupus erythematosus, with Phase I completed and further clinical development progressing. The Sofra platform also supports programs across inflammatory and autoimmune diseases, RNA therapeutics and oncology, according to the filing.




Please wait processing your request...